Rhythm Pharmaceuticals (RYTM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on the stock and has a $68.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tazeen Ahmad’s rating is based on the promising outlook for Rhythm Pharmaceuticals, particularly due to the positive Phase 3 trial results for setmelanotide in treating hypothalamic obesity (HO). The trial showed a significant reduction in body mass index, which is a notable achievement given the lack of approved therapies for HO. The CEO, David Meeker, expressed confidence in the drug’s risk/benefit profile and the company’s plans to file a supplementary New Drug Application in the third quarter, with expectations for a priority review without the need for an advisory committee.
Additionally, the company sees a strong commercial opportunity in the HO market, estimating a prevalent population of 5,000 to 10,000 in the U.S., which is well-managed by endocrinologists. Rhythm Pharmaceuticals plans to expand its salesforce to effectively cover this market. The company also anticipates a steady growth trajectory for its Imcivree franchise in Bardet-Biedl syndrome (BBS) and has strategies in place to mitigate potential macroeconomic impacts. These factors contribute to the Buy rating, supported by a price objective of $68, indicating potential upside from the current price.
In another report released on April 10, Canaccord Genuity also maintained a Buy rating on the stock with a $92.00 price target.
RYTM’s price has also changed moderately for the past six months – from $50.190 to $60.480, which is a 20.50% increase.